GGrantIndex
← Leaderboards

Naftali Kaminski

Yale University

$42,947,928
Attributed
$74,951,591
Total exposure
20
Grants
13
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $10.1M · FY200525
$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$74,951,591 · 20

By mechanism

R01$17,634,176 · 5
U01$17,234,144 · 4
RC2$14,890,943 · 2
UH3$9,549,597 · 2
T32$7,384,700 · 1
P50$3,038,548 · 1

Most similar at Yale University

Same institution · by research overlap

Others in their field

Top investigators on “Lung

Research focus

LungCellsTissuesPhenotypeFibrosisGene ExpressionGenomicsPathway InteractionsLung DiseasesResponseValidationAffectBaseExtracellular MatrixChronicStructure Of Parenchyma Of LungMolecularGenesDesignComputational BiologyPatternSamplingEpithelial CellsResearch Personnel

Grant awards (88)

Genomic Analysis of Tissue and Cellular Heterogeneity in IPF$698,173
R01 · FY2025 · HL · contact PI
Genomic Analysis of Tissue and Cellular Heterogeneity in IPF$685,000
R01 · FY2024 · HL · contact PI
Training in Translational Lung Biology and Pathobiology$552,994
T32 · FY2024 · HL · contact PI
Genomic Analysis of Tissue and Cellular Heterogeneity in IPF$90,433
R01 · FY2024 · HL · contact PI
Training in Translational Lung Biology and Pathobiology$872,892
T32 · FY2023 · HL · contact PI
Genomic Analysis of Tissue and Cellular Heterogeneity in IPF$707,519
R01 · FY2023 · HL · contact PI
Integrating single-cell based transcriptomic signatures for identifying therapeutic targets of COPD$125,625
R21 · FY2023 · HL · contact PI
Genomic Analysis of Tissue and Cellular Heterogeneity in IPF$90,433
R01 · FY2023 · HL · contact PI
Epithelial Protective Effects of Thyroid Hormone Signaling in Fibrosis$788,105
R01 · FY2022 · HL · contact PI
Genomic Analysis of Tissue and Cellular Heterogeneity in IPF$750,208
R01 · FY2022 · HL · contact PI
Training in Translational Lung Biology and Pathobiology$630,511
T32 · FY2022 · HL · contact PI
Normal Aging Lung Cell Atlas (NALCA)$626,104
U01 · FY2022 · HL · contact PI
Integrating single-cell based transcriptomic signatures for identifying therapeutic targets of COPD$125,625
R21 · FY2022 · HL · contact PI
Normal Aging Lung Cell Atlas (NALCA)$86,005
U01 · FY2022 · HL · contact PI
Use of the Src Family Kinase Inhibitor Saracatinib in the Treatment of Pulmonary Fibrosis$1,511,058
UH3 · FY2021 · TR
Epithelial Protective Effects of Thyroid Hormone Signaling in Fibrosis$879,865
R01 · FY2021 · HL · contact PI
Training in Translational Lung Biology and Pathobiology$805,700
T32 · FY2021 · HL · contact PI
Normal Aging Lung Cell Atlas (NALCA)$641,786
U01 · FY2021 · HL · contact PI
Normal Aging Lung Cell Atlas (NALCA)$86,005
U01 · FY2021 · HL · contact PI
Use of the Src Family Kinase Inhibitor Saracatinib in the Treatment of Pulmonary Fibrosis$1,726,316
UH3 · FY2020 · TR
Epithelial Protective Effects of Thyroid Hormone Signaling in Fibrosis$826,057
R01 · FY2020 · HL · contact PI
Training in Translational Lung Biology and Pathobiology$800,827
T32 · FY2020 · HL · contact PI
Normal Aging Lung Cell Atlas (NALCA)$662,572
U01 · FY2020 · HL · contact PI
Epithelial Protective Effects of Thyroid Hormone Signaling in Fibrosis$69,985
R01 · FY2020 · HL · contact PI
Use of the Src Family Kinase Inhibitor Saracatinib in the Treatment of Pulmonary Fibrosis$1,672,515
UH3 · FY2019 · TR
Epithelial Protective Effects of Thyroid Hormone Signaling in Fibrosis$803,109
R01 · FY2019 · HL · contact PI
Normal Aging Lung Cell Atlas (NALCA)$731,345
U01 · FY2019 · HL · contact PI
Training in Translational Lung Biology and Pathobiology$318,152
T32 · FY2019 · HL · contact PI
Use of the Src Family Kinase Inhibitor Saracatinib in the Treatment of Pulmonary Fibrosis$97,416
UH3 · FY2019 · TR
Mir-29 mimicry as a therapy for pulmonary fibrosis$1,387,947
UH3 · FY2018 · HL · contact PI
Use of the Src Family Kinase Inhibitor Saracatinib in the Treatment of Pulmonary Fibrosis$853,963
UG3 · FY2018 · TR
Alveolar DevMAP$734,685
U01 · FY2018 · HL
Genomic Analysis of Tissue and Cellular Heterogeneity in IPF$685,322
R01 · FY2018 · HL · contact PI
Training in Translational Lung Biology and Pathobiology$676,294
T32 · FY2018 · HL · contact PI
Mir-29 mimicry as a therapy for pulmonary fibrosis$1,719,886
UH3 · FY2017 · HL · contact PI
Alveolar DevMAP$742,417
U01 · FY2017 · HL
Genomic Analysis of Tissue and Cellular Heterogeneity in IPF$702,354
R01 · FY2017 · HL · contact PI
Training in Translational Lung Biology and Pathobiology$555,990
T32 · FY2017 · HL · contact PI
Training in Translational Lung Biology and Pathobiology$1,318
T32 · FY2017 · HL · contact PI
Mir-29 mimicry as a therapy for pulmonary fibrosis$1,434,459
UH3 · FY2016 · HL · contact PI
Alveolar DevMAP$734,777
U01 · FY2016 · HL
Genomic Analysis of Tissue and Cellular Heterogeneity in IPF$713,806
R01 · FY2016 · HL · contact PI
Training in Translational Lung Biology and Pathobiology$657,856
T32 · FY2016 · HL · contact PI
Sarcoidosis and A1AT Genomics & Informatics Center$2,447,769
U01 · FY2015 · HL
Mir-29 mimicry as a therapy for pulmonary fibrosis$1,278,604
UH2 · FY2015 · HL · contact PI
Genomic Analysis of Tissue and Cellular Heterogeneity in IPF$818,314
R01 · FY2015 · HL · contact PI
Alveolar DevMAP$734,976
U01 · FY2015 · HL
Training in Translational Lung Biology and Pathobiology$639,677
T32 · FY2015 · HL · contact PI
Mir-29 mimicry as a therapy for pulmonary fibrosis$1,431,654
UH2 · FY2014 · HL · contact PI
Alveolar DevMAP$740,050
U01 · FY2014 · HL
Gene networks beyond organ boundaries; heart, lung and pulmonary vascular disease$497,772
U01 · FY2014 · HL · contact PI
Sarcoidosis and A1AT Genomics & Informatics Center$390,000
U01 · FY2014 · HL
Training in Respiratory Biology and Pathobiology$267,177
T32 · FY2014 · HL · contact PI
Sarcoidosis and A1AT Genomics & Informatics Center$3,628,231
U01 · FY2013 · HL
Training in Respiratory Biology and Pathobiology$605,312
T32 · FY2013 · HL · contact PI
Gene networks beyond organ boundaries; heart, lung and pulmonary vascular disease$517,785
U01 · FY2013 · HL · contact PI
Sarcoidosis and A1AT Genomics & Informatics Center$2,068,387
U01 · FY2012 · HL · contact PI
Gene networks beyond organ boundaries; heart, lung and pulmonary vascular disease$581,739
U01 · FY2012 · HL · contact PI
Molecular Phenotypes within and across disease boundaries in IPF and COPD$711,424
R01 · FY2011 · HL · contact PI
Gene networks beyond organ boundaries; heart, lung and pulmonary vascular disease$581,739
U01 · FY2011 · HL · contact PI
Modeling in vivo Protein-DNA Interactions from High-Throughput Data MP1/1$465,349
R01 · FY2011 · LM
Lung Genomics Research Consortium$3,759,656
RC2 · FY2010 · HL
Linking Genetics, Genomics and Phenomics to Better Understand Asthma Severity$1,787,959
RC2 · FY2010 · HL
Lung Genomics Research Consortium$1,654,805
RC2 · FY2010 · HL
Molecular Phenotypes within and across disease boundaries in IPF and COPD$718,962
R01 · FY2010 · HL · contact PI
Surrogate Biomarkers for Disease Progression in IPF$516,024
P50 · FY2010 · HL · contact PI
Genome-Wide Association and Exon Sequencing Study in IPF$500,000
RC1 · FY2010 · HL
Modeling in vivo Protein-DNA Interactions from High-Throughput Data MP1/1$470,983
R01 · FY2010 · LM
Lung Genomics Research Consortium$5,987,215
RC2 · FY2009 · HL
Linking Genetics, Genomics and Phenomics to Better Understand Asthma Severity$1,701,308
RC2 · FY2009 · HL
Molecular Phenotypes within and across disease boundaries in IPF and COPD$738,001
R01 · FY2009 · HL · contact PI
Surrogate Biomarkers for Disease Progression in IPF$501,914
P50 · FY2009 · HL · contact PI
Genome-Wide Association and Exon Sequencing Study in IPF$500,000
RC1 · FY2009 · HL
Modeling in vivo Protein-DNA Interactions from High-Throughput Data MP1/1$462,252
R01 · FY2009 · LM
Modeling in vivo Protein-DNA Interactions from High-Throughput Data MP1/1$224,578
R01 · FY2009 · LM
Molecular Phenotypes within and across disease boundaries in IPF and COPD$18,265
R01 · FY2009 · HL · contact PI
Surrogate Biomarkers for Disease Progression in IPF$771,211
P50 · FY2008 · HL · contact PI
Molecular Phenotypes within and across disease boundaries in IPF and COPD$770,981
R01 · FY2008 · HL · contact PI
Modeling in vivo Protein-DNA Interactions from High-Throughput Data MP1/1$449,157
R01 · FY2008 · LM
Surrogate Biomarkers for Disease Progression in IPF$693,698
P50 · FY2007 · HL · contact PI
Modeling in vivo Protein-DNA Interactions from High-Throughput Data MP1/1$450,324
R01 · FY2007 · LM
New Molecular Targets in Pulmonary Fibrosis$698,530
R01 · FY2006 · HL · contact PI
Surrogate Biomarkers for Disease Progression in IPF$555,701
P50 · FY2006 · HL · contact PI
Proteomics of Idiopathic Pulmonary Fibrosis$181,262
R21 · FY2006 · HL · contact PI
New Molecular Targets in Pulmonary Fibrosis$715,825
R01 · FY2005 · HL
Proteomics of Idiopathic Pulmonary Fibrosis$222,750
R21 · FY2005 · HL
New Molecular Targets in Pulmonary Fibrosis$717,280
R01 · FY2004 · HL
New Molecular Targets in Pulmonary Fibrosis$713,582
R01 · FY2003 · HL